GLP-1 receptor agonists are the fastest-growing drug class in the United States by prescription volume and cost in 2026. Semaglutide (Ozempic for type 2 diabetes, Wegovy for chronic weight management, Rybelsus as an oral tablet) and tirzepatide (Mounjaro for type 2 diabetes, Zepbound for obesity) are self-administered weekly injectable medications. Their retail list prices range from $935 to $1,349 per month, placing them among the most expensive widely-prescribed outpatient drugs in the country. ACA marketplace plans treat these drugs very differently depending on whether the diagnosis is type 2 diabetes or obesity, a distinction that can mean the difference between a $30 copay and a $1,000+ monthly cash bill.
GLP-1 drugs prescribed for type 2 diabetes benefit from broad formulary coverage because diabetes medications are considered standard of care. Across ACA marketplace plans in 2026, 82% include Ozempic and 51% include Mounjaro on their formularies for the diabetes indication, according to Kaiser Family Foundation (KFF) analysis. Almost all plans that cover these drugs require prior authorization, and 96% apply quantity limits. Patients enrolled in commercial marketplace plans and receiving Ozempic for diabetes can often access the Novo Nordisk savings card at $25 per month for commercially insured patients, though this manufacturer coupon cannot be used by anyone covered under Medicare, Medicaid, TRICARE, or VA benefits per federal anti-kickback statute (42 U.S.C. § 1320a-7b). Coverage for the diabetes indication is also subject to step therapy requirements at many plans, where insurers may require a trial of metformin before approving a GLP-1.
GLP-1 drugs prescribed for obesity face an entirely different coverage landscape on the ACA marketplace. Weight-loss medications are not classified as essential health benefits under the Affordable Care Act, which means no federal law requires marketplace plans to cover them. As of 2026, only 26 of 300 ACA marketplace carriers (8.7%) offer any coverage for GLP-1 obesity drugs such as Wegovy or Zepbound, and that number has declined from 3.6 million enrolled patients in 2024 to approximately 2.8 million in 2026. The Inflation Reduction Act selected semaglutide (Ozempic, Rybelsus, Wegovy) for the second round of Medicare price negotiation, with negotiated prices scheduled to take effect in 2027. Marketplace patients should note that IRA Round-2 negotiated prices apply to Medicare, not to ACA marketplace plans directly, but competitive pressure from the 2027 Medicare Maximum Fair Price may influence marketplace formulary positioning going forward.
What GLP-1 ACA Coverage Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same glp-1 aca coverage can cost many times more at a hospital than at your local pharmacy:
2026 GLP-1 ACA Coverage Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Pharmacy counter (retail, cash, no insurance) | $935 - $1,349/month | 2026 list prices: Ozempic $935-$969, Wegovy $1,349, Mounjaro $1,069, Zepbound $1,029 per month |
| ACA marketplace plan (diabetes indication, 2026) | $30 - $150/month after PA and deductible | 82% of plans cover Ozempic for T2D; 51% cover Mounjaro. Almost all require prior authorization and formulary tier placement at specialty or non-preferred tier. |
| ACA marketplace plan (obesity/weight loss indication, 2026) | $50 - $300/month (if covered); most plans: not covered | Only 26 of 300 marketplace carriers cover GLP-1s for obesity in 2026. 9 states have plans with obesity coverage: CA, ND, NY, VT, PA, WV, RI, DE, GA. |
| Manufacturer savings card (commercial insurance only) | $25/month (Ozempic, commercially insured); $0-$225/month (Wegovy) | Cannot be used with Medicare, Medicaid, TRICARE, or VA. Anti-kickback statute (42 U.S.C. § 1320a-7b) prohibits use with federal coverage. |
| Medicaid (varies by state, 2026) | $1 - $10/prescription with PA (diabetes); obesity coverage in ~13 states | Medicaid covers GLP-1s for type 2 diabetes broadly. Weight-loss GLP-1 coverage varies; about 13 states covered obesity GLP-1s as of 2026. |
ACA marketplace prices reflect 2026 formulary data from KFF and CMS analyses. Individual plan costs vary by metal tier, formulary tier, and deductible status. Retail list prices verified via GoodRx and manufacturer sites, June 2026.
Source: KFF ACA Marketplace Analysis 2026, CMS Essential Health Benefits data, GoodRx, NovoCare, LillyDirect
Why Hospitals Charge So Much
GLP-1 drugs are outpatient, self-administered prescriptions, so you rarely encounter them on an inpatient hospital bill. When GLP-1 drugs do appear on a hospital itemized bill, it is usually because the admitting facility dispensed a pen or syringe to bridge a gap in outpatient therapy during a hospitalization, or because a patient had a pen in their possession that was logged as part of the medication reconciliation. Hospital pharmacy departments apply the same facility markup structure to GLP-1 pens that they apply to all other drugs, which means the acquisition cost is layered with pharmacy handling fees, nursing administration charges, and overhead allocations. A single Ozempic pen that retails for $969 at a community pharmacy can appear on an inpatient bill at $1,500 to $2,800.
Three structural factors drive this markup. First, hospital pharmacies purchase drugs at the wholesale acquisition cost and then apply a facility charge multiplier (typically 1.5x to 3x) before billing. Second, many hospitals operate under a 340B drug pricing program exemption that allows discounted acquisition prices, but they still bill insurers and patients at the full retail rate and retain the difference. Third, inpatient billing encodes GLP-1 dispensing under pharmacy revenue codes (revenue code 250-258), which insurers reimburse at facility rates rather than outpatient pharmacy rates. If you receive a hospital bill showing a GLP-1 drug at more than 150% of the current list price, request the National Drug Code (NDC) from the itemized bill, look up the 2026 wholesale acquisition cost at goodrx.com, and dispute the markup in writing with the hospital's patient financial services office.
Patient Assistance Programs
Novo Nordisk (manufacturer of Ozempic, Wegovy, Rybelsus) and Eli Lilly (manufacturer of Mounjaro, Zepbound, Trulicity) each run manufacturer direct programs and patient assistance programs that substantially lower GLP-1 costs for uninsured and commercially insured patients. For patients without any prescription drug insurance, the cash prices through these programs range from $149 to $499 per month in 2026, far below the retail list price of $935 to $1,349. Patients on Medicare or Medicaid are not eligible for manufacturer savings cards but may qualify for the income-based patient assistance program.
Patient assistance programs for GLP-1 ACA Coverage| Manufacturer program | Cost / Benefit | How to apply |
|---|
| NovoCare Patient Assistance Program (Ozempic) | Free Ozempic for uninsured patients with income at or below 200% of federal poverty level ($31,920 for a single person in 2026). Medicare Part D beneficiaries no longer eligible as of 2026. | novocare.com/diabetes/help-with-costs/pap |
| NovoCare Patient Assistance Program (Wegovy, Rybelsus, and other NN drugs) | Free medication for uninsured patients with income at or below 400% of federal poverty level ($63,840 for a single person in 2026). Must have no other prescription drug coverage. | novocare.com/diabetes/help-with-costs/pap |
| Ozempic Savings Card (Novo Nordisk) | $25/month for up to 24 months for commercially insured patients with type 2 diabetes. Not valid with Medicare, Medicaid, TRICARE, or VA. | ozempic.com/savings-and-resources/save-on-ozempic |
| NovoCare Direct (Wegovy pens, self-pay, no insurance required) | $199-$399/month for Wegovy pens ordered directly from Novo Nordisk. No insurance required. 2026 self-pay pharmacy program. | novocare.com/pharmacy |
| Lilly Cares Foundation Patient Assistance Program (Mounjaro, Zepbound, Trulicity) | Free or reduced-cost tirzepatide for uninsured patients with household income at or below 400% of federal poverty level. Income limits and covered products vary. | lillycares.com |
| LillyDirect Self-Pay (Zepbound vials, no insurance required) | $349/month (2.5 mg/5 mg vials), $499/month (7.5 mg/10 mg), $599/month (12.5 mg/15 mg). Ordered directly from LillyDirect, no insurance or intermediary. | lilly.com/lillydirect/medicines/zepbound |
| NeedyMeds Drug Discount Card | Variable discount accepted at most US pharmacies. Typically reduces GLP-1 cost 5 to 15% below retail list price. Free card, no enrollment. | needymeds.org |
Manufacturer savings cards (Ozempic Savings Card, Wegovy Savings Offer, Mounjaro Savings Card, Zepbound Savings Card) are not available to anyone covered by Medicare, Medicaid, TRICARE, or VA benefits under federal anti-kickback statute (42 U.S.C. § 1320a-7b). If you have government coverage, apply for the NovoCare Patient Assistance Program or Lilly Cares Foundation program instead. Self-pay direct programs (NovoCare Direct, LillyDirect) are available regardless of insurance status.
Source: NovoCare 2026 PAP eligibility page, Lilly Cares Foundation, NeedyMeds.org, LillyDirect.com
Medicare Part D
Medicare Part D covers GLP-1 drugs for their FDA-approved indications. Ozempic (semaglutide for type 2 diabetes) and Mounjaro (tirzepatide for type 2 diabetes) are covered by most Part D plans when prescribed for diabetes. The 2026 Medicare Part D annual out-of-pocket cap is $2,000 under the Inflation Reduction Act. Once you reach $2,000 in out-of-pocket Part D spending across all covered drugs in a calendar year, you pay $0 for the rest of the year. Medicare does not cover Wegovy (semaglutide for weight management) or Zepbound (tirzepatide for obesity) under the standard Part D weight-loss drug exclusion (42 U.S.C. § 1395w-102(e)(2)(A)), except in limited cardiovascular risk-reduction cases authorized by CMS in 2024.
Starting July 1, 2026, a new Medicare GLP-1 Bridge program covers Wegovy (semaglutide) and Zepbound (tirzepatide KwikPen) for weight management at a flat $50 monthly copay for Medicare beneficiaries who meet clinical criteria: a BMI of 30 or higher (or 27 with an obesity-related comorbidity) and documented participation in a behavioral health program. This program is separate from standard Medicare Part D and is administered through a CMS demonstration model. The IRA's Round-2 Medicare negotiation for semaglutide (Ozempic, Wegovy, Rybelsus) is scheduled to produce a negotiated Maximum Fair Price effective 2027, which will apply to all Medicare Part D purchases of those drugs.
Medicare beneficiaries who can no longer access manufacturer savings cards due to the federal anti-kickback statute should contact NovoCare at 1-866-310-7549 or Lilly Cares Foundation at 1-800-545-5979 to apply for the income-based patient assistance program. Note that as of 2026, Medicare Part D beneficiaries are no longer eligible for the NovoCare PAP for Ozempic specifically, because most Medicare Part D plans now cover Ozempic for type 2 diabetes. Patients with very high cost-sharing under their Part D plan should ask about the Medicare Prescription Payment Plan, which spreads 2026 out-of-pocket costs evenly across 12 months.
Common GLP-1 ACA Coverage Billing Errors
If you receive an unexpected bill or coverage denial for a GLP-1 drug through your ACA marketplace plan, check for these common 2026 billing and coding errors before paying:
- Wrong ICD-10 code submitted by prescriber: Ozempic requires a type 2 diabetes diagnosis code (E11.x) to clear formulary coverage. If your prescriber coded it under obesity (E66.x) or weight management (Z68.x), the claim will be rejected even if you have diabetes. Ask the prescribing office to verify the diagnosis code submitted.
- Prior authorization not submitted before the first fill: most ACA marketplace plans require PA for all GLP-1 drugs. Filling without an approved PA means you pay the full retail price. Confirm PA approval before picking up the prescription.
- Wegovy or Zepbound billed under Ozempic or Mounjaro codes: these products have different NDCs and different coverage rules. A plan that covers Ozempic for diabetes will deny a claim filed under Wegovy's NDC. Confirm the dispensed product's NDC matches the coverage determination.
- Manufacturer savings card applied to a Medicare or Medicaid claim: pharmacies sometimes attempt to stack a manufacturer coupon on top of a federal coverage claim. This violates the anti-kickback statute and results in a rejected claim. If you have federal coverage, only the income-based patient assistance program (NovoCare PAP or Lilly Cares) applies.
- Step therapy not documented: if your plan requires a step-therapy trial of metformin before approving a GLP-1, and the prescriber did not document metformin failure, your claim will be denied. Ask the prescribing office to include the step-therapy documentation with the PA request.
Frequently Asked Questions
Does my ACA marketplace plan cover GLP-1 drugs for weight loss in 2026?
Most ACA marketplace plans do not cover GLP-1 drugs for weight loss in 2026. Only 26 of 300 marketplace carriers (8.7%) offer coverage for Wegovy, Zepbound, or similar drugs for obesity. Weight-loss medications are not classified as essential health benefits under federal law, so coverage is entirely voluntary. Nine states have at least one carrier offering obesity GLP-1 coverage: California, North Dakota, New York, Vermont, Pennsylvania, West Virginia, Rhode Island, Delaware, and Georgia. Check your plan's formulary by calling the number on your insurance card and asking specifically about the NDC for Wegovy (semaglutide 2.4 mg) or Zepbound (tirzepatide).
Does my ACA marketplace plan cover Ozempic or Mounjaro for type 2 diabetes in 2026?
Yes, most ACA marketplace plans cover GLP-1 drugs when prescribed for type 2 diabetes. Across marketplace plans in 2026, 82% include Ozempic (semaglutide) and 51% include Mounjaro (tirzepatide) on their formulary for the diabetes indication, based on KFF analysis. Almost all require prior authorization, and 96% apply quantity limits. If covered, these drugs are typically placed on a specialty or non-preferred tier, with copays or coinsurance ranging from $30 to $150 per month after meeting your deductible. Confirm your specific plan's formulary tier at healthcare.gov or by calling your insurer.
How do I apply for the NovoCare Patient Assistance Program for Ozempic or Wegovy?
Visit novocare.com/diabetes/help-with-costs/pap or call 1-866-310-7549. For Ozempic, income must be at or below 200% of the federal poverty level (up to $31,920 for a household of 1 in 2026). For Wegovy and other Novo Nordisk drugs, the limit is 400% FPL (up to $63,840 for a household of 1 in 2026). You must be uninsured or have Medicare without Part D coverage. Gather your most recent tax return or pay stubs, proof of US residency, a valid prescription, and a statement that you have no prescription drug coverage. Submit by fax or online. Processing takes 7 to 14 business days. As of 2026, most Medicare Part D beneficiaries are no longer eligible for the Ozempic PAP because Part D now broadly covers it.
Can I use the Ozempic or Wegovy savings card if I have a marketplace plan?
Yes, if your coverage is a commercial ACA marketplace plan, you can use the manufacturer coupon or savings card. The Ozempic Savings Card caps your monthly cost at $25 for commercially insured patients with type 2 diabetes for up to 24 months. The Wegovy Savings Offer varies by plan coverage. These savings cards are blocked by federal anti-kickback statute (42 U.S.C. § 1320a-7b) for anyone on Medicare, Medicaid, TRICARE, or VA, but a marketplace plan is a commercial plan, so the savings card applies. Present the savings card BIN and PCN at the pharmacy counter when picking up the prescription.
What if my marketplace plan denies coverage for a GLP-1 drug?
Request the written denial notice and verify the reason: missing prior authorization, step-therapy requirement, formulary exclusion, or wrong ICD-10 code. Have your prescriber file a letter of medical necessity that directly addresses the denial reason. Peer-to-peer review between your prescriber and the insurer's medical reviewer increases approval rates to up to 80%. If internal appeals fail, request an external independent review through your state department of insurance (free under ACA rules). Fallback options include the NovoCare Direct self-pay program ($199 to $399 per month) or LillyDirect ($349 to $599 per month), both available without insurance.
Is there a generic GLP-1 drug available in 2026?
No. No FDA-approved generic or biosimilar equivalent to semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound) exists as of June 2026. Semaglutide's core patent is expected to expire around 2031, after which generic competition is possible. The FDA in 2026 also proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, which limits compounding pharmacies' legal access to these active ingredients. Older GLP-1 agents such as exenatide and liraglutide are available at lower costs and may be on your plan's formulary as diabetes alternatives.
Does the Inflation Reduction Act reduce GLP-1 costs for marketplace patients in 2026?
Not directly in 2026. The Inflation Reduction Act Round-1 negotiated prices apply only to the 10 Medicare Part D drugs with Maximum Fair Prices effective 2026-01-01 (Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and Fiasp/NovoLog). Semaglutide (Ozempic, Wegovy, Rybelsus) was selected for Round-2 Medicare negotiation, with a negotiated Maximum Fair Price scheduled to take effect in 2027 for Medicare beneficiaries. The IRA Medicare drug price negotiation does not directly reduce prices for ACA marketplace or employer-sponsored plan enrollees, though competitive pricing pressure may influence those markets over time.
What is the Medicare GLP-1 Bridge program, and does it apply to ACA marketplace patients?
The Medicare GLP-1 Bridge program, launching July 1, 2026, provides Wegovy (semaglutide) and Zepbound (tirzepatide KwikPen) for weight management at a flat $50 monthly copay for Medicare beneficiaries who have a BMI of 30 or higher (or 27 with an obesity-related comorbidity) and participate in a behavioral health program. This program applies only to Medicare beneficiaries and is administered through a CMS demonstration model. ACA marketplace enrollees are not eligible for the Medicare GLP-1 Bridge program. Marketplace patients should instead check whether their plan covers Wegovy or Zepbound for obesity, or use the NovoCare Direct or LillyDirect self-pay options.
